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IMPORTANCE Triglycerides and cholesterol are both carried in plasma by apolipoprotein B
(ApoB)–containing lipoprotein particles. It is unknownwhether lowering plasma triglyceride
levels reduces the risk of cardiovascular events to the same extent as lowering low-density
lipoprotein cholesterol (LDL-C) levels.
OBJECTIVE To compare the association of triglyceride-lowering variants in the lipoprotein
lipase (LPL) gene and LDL-C–lowering variants in the LDL receptor gene (LDLR) with the risk
of cardiovascular disease per unit change in ApoB.
DESIGN, SETTING, AND PARTICIPANTS Mendelian randomization analyses evaluating the
associations of genetic scores composed of triglyceride-lowering variants in the LPL gene and
LDL-C–lowering variants in the LDLR gene, respectively, with the risk of cardiovascular events
among participants enrolled in 63 cohort or case-control studies conducted in North America
or Europe between 1948 and 2017.
EXPOSURES Differences in plasma triglyceride, LDL-C, and ApoB levels associated with the
LPL and LDLR genetic scores.
MAIN OUTCOMES ANDMEASURES Odds ratio (OR) for coronary heart disease (CHD)—defined
as coronary death, myocardial infarction, or coronary revascularization—per 10-mg/dL lower
concentration of ApoB-containing lipoproteins.
RESULTS A total of 654 783 participants, including 91 129 cases of CHD, were included
(mean age, 62.7 years; 51.4%women). For each 10-mg/dL lower level of ApoB-containing
lipoproteins, the LPL score was associated with 69.9-mg/dL (95% CI, 68.1-71.6;
P = 7.1 × 10−1363) lower triglyceride levels and 0.7-mg/dL (95% CI, 0.03-1.4; P = .04) higher
LDL-C levels; while the LDLR score was associated with 14.2-mg/dL (95% CI, 13.6-14.8;
P = 1.4 × 10−465) lower LDL-C and 1.9-mg/dL (95% CI, 0.1-3.9; P = .04) lower triglyceride
levels. Despite these differences in associated lipid levels, the LPL and LDLR scores were
associated with similar lower risk of CHD per 10-mg/dL lower level of ApoB-containing
lipoproteins (OR, 0.771 [95% CI, 0.741-0.802], P = 3.9 × 10−38 and OR, 0.773 [95% CI,
0.747-0.801], P = 1.1 × 10−46, respectively). In multivariable mendelian randomization
analyses, the associations between triglyceride and LDL-C levels with the risk of CHD became
null after adjusting for differences in ApoB (triglycerides: OR, 1.014 [95% CI, 0.965-1.065],
P = .19; LDL-C: OR, 1.010 [95% CI, 0.967-1.055], P = .19; ApoB: OR, 0.761 [95% CI,
0.723-0.798], P = 7.51 × 10−20).
CONCLUSIONS AND RELEVANCE Triglyceride-lowering LPL variants and LDL-C–lowering LDLR
variants were associated with similar lower risk of CHD per unit difference in ApoB. Therefore,
the clinical benefit of lowering triglyceride and LDL-C levels may be proportional to the
absolute change in ApoB.
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A ll major clinical guidelines recommend treatment tolower plasma low-density lipoprotein cholesterol(LDL-C) because numerous randomized trials have
demonstrated that therapies that lower LDL-C levels by re-
ducing LDL particles through upregulation of the LDL recep-
tor (LDLR) reduce the risk of cardiovascular events.1-5 By con-
trast, the guidelines do not recommend treatment to lower
plasma triglyceride levels because randomized trials havenot
provided consistent evidence that lowering plasma triglycer-
ide levels reduces the risk of cardiovascular events.1,2
Severalnovel therapiesthatpotentlyreducetriglyceride lev-
els are currently indevelopment.6-8 Thedevelopment of these
therapieshasbeenmotivatedinpartbytheobservationthatrare
loss-of-functionmutations in the lipoprotein lipase (LPL) gene
areassociatedwithhigherplasmatriglyceridelevelsandahigher
riskof cardiovasculardisease;while rare, loss-of-functionmu-
tations in the APOC3, ANGPTL3, and ANGPTL4 genes, which
encode for natural inhibitors of LPL, are associatedwith lower
triglyceride levels anda corresponding lower riskof cardiovas-
cular disease.9-13 However, it is unknown whether lowering
plasma triglyceride levels by targeting theLPLpathwaywill re-
duce the risk of cardiovascular events.
Both triglycerides andcholesterol are carried inplasmaby
apolipoproteinB (ApoB)–containing lipoproteinparticles. Be-
causeallApoB-containing lipoproteins, including triglyceride-
rich lipoproteinparticles andLDLparticles, havea singleApoB
molecule the clinical benefit of lowering triglyceride levels can
be compared with the clinical benefit of lowering LDL-C lev-
els by estimating their effects per unit change inApoB. There-
fore, theobjectiveof this studywas tousemendelian random-
ization tocompare theassociationof triglyceride-loweringLPL
variantsandLDL-C–loweringLDLRvariantswith theriskofcar-
diovascular disease per unit difference inApoB tomake infer-
ences about the potential clinical benefit of lowering plasma
triglyceride levels as compared with lowering LDL-C levels.
Methods
Study Population
Thestudyincludedindividualparticipantdatafrom367641par-
ticipants enrolled in the UK Biobank study, individual partici-
pant data from 102837participants enrolled in 1 of 14 prospec-
tive cohort or case-control studies that reported data on
cardiovascularoutcomes in theUSNationalCenter forBiotech-
nologyInformationDatabaseofGenotypesandPhenotypespro-
gram (dbGAP), and summary-level data from 184305 partici-
pants enrolled in 1 of 48 prospective cohort, case-control, or
cross-sectional studies included in the Coronary Artery Dis-
easeGenomewideReplicationandMeta-Analysisplus theCoro-
nary Artery Disease (CARDIoGRAMplusC4D) Consortium.14-16
Participants of European descent in the UK Biobank, and all
racial/ethnic groups for which cardiovascular data were re-
ported in the dbGAP and CARDIoGRAMplusC4D Consortium
studies, were included in the analysis. In each included study,
race/ethnicity was self-identified using a study-specific fixed-
category questionnaire andwas recorded to allow assessment
of potential heterogeneity of effect estimates by ethnicity.
Contributing studies received ethical approval from their
respective institutional review boards, and written informed
consent was obtained from all participants. A description of
the includedstudiesandthegenotypingplatformsused ineach
study is provided in eTable 1 in the Supplement.
Genetic Instruments
The LPL genetic score was constructed by combining all vari-
ants within 100kb on either side of the LPL gene that were
associated with plasma triglyceride levels at genome-wide
level of significance (P < 5.0 × 10−8) as reported by the Global
Lipids Genetics Consortium and that were in low linkage dis-
equilibrium (r2 < 0.3) with all other variants included in the
score.17,18 The LDLR genetic score was constructed similarly
by combining all variants within 100kb on either side of the
LDLR gene that were associated with plasma LDL-C levels at
genome-wide level of significance and that were in low link-
age disequilibrium (r2 < 0.3) with all other variants included
in the score. The exposure allele for each LPL variant was
defined as the allele associated with lower plasma triglycer-
ide levels, and the exposure allele for each LDLR variant was
defined as the allele associated with lower LDL-C levels.17,18
For each participant, an LPL genetic score was calculated by
summing the number of triglyceride-lowering alleles that
participants inherited at each variant included in the LPL
score and an LDLR score was calculated by summing the
number of LDL-C–lowering alleles that participants inherited
at each variant included in the LDLR score. Participants were
excluded if they had missing data for 1 or more variants
included in either genetic score.
Study Outcomes
Theprimaryclinicaloutcomewascoronaryheartdisease (CHD)
defined as a composite of prevalent or the first incident occur-
rence of myocardial infarction (MI), coronary revasculariza-
tion, or coronary death. For analyses involving individual par-
ticipant data, the primary clinical outcome was harmonized
across all included studies. For analyses involving summary-
level data, the definition of CHD was defined by each study
included in the CARDIoGRAMplusC4D consortium, which in-
cluded CHD death, MI, and coronary revascularization but
Key Points
Question What is the clinical benefit of lowering plasma
triglyceride levels compared with lowering low-density lipoprotein
cholesterol levels?
Findings In mendelian randomization analyses involving 654 783
participants, triglyceride-lowering variants in the lipoprotein lipase
gene and low-density lipoprotein cholesterol (LDL-C)–lowering
variants in the LDL receptor gene were associated with similar
lower risk of coronary heart disease per 10-mg/dL lower level of
apolipoprotein B (ApoB)–containing lipoproteins (odds ratios
of 0.771 and 0.773, respectively).
Meaning The clinical benefit of lower triglyceride levels was
similar to the clinical benefit of lower LDL-C levels per unit
difference in ApoB andmay be related to the absolute reduction
in ApoB-containing lipoprotein particles.
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insomestudiesalso includedchronicstableanginaormorethan
50% stenosis in amajor epicardial coronary artery.16
Study Design and Statistical Analysis
Adescriptionof thestudydesign,analysesperformed,anddata
used for eachanalysis is provided ineFigures 1-3 in theSupple-
ment. The association of each genetic score with plasma tri-
glycerides,LDL-C, andApoBwasevaluatedusing linear regres-
sion andwithCHD risk using logistic regression. All regression
analyseswereperformedseparately ineachoftheincludedstud-
ies adjusting for age, sex, and the first 5 principal components
ofancestry.Todirectly compare theclinicalbenefit of lower tri-
glyceride levels due to the LPL score with lower LDL-C levels
due to the LDLR genetic score, the associations of each score
with riskofCHDwasscaled foracommon10-mg/dL lower level
ofApoB-containinglipoproteins.For individualparticipantdata,
thescaledpointestimateswereobtainedbyweightingeachvari-
ant included in either genetic score by its associated change in
ApoB.Forsummary-leveldata, thescaledassociationswereob-
tainedbydividing thereportedpointestimate (andstandarder-
ror) for an outcome by the reported point estimate for ApoB
(measured inmg/dL). The scaled summarypoint estimates for
all variants included in a score were then combined in a fixed-
effect inversevariance-weightedmeta-analysis toestimate the
association between that genetic score generated using sum-
marydataandtheoutcomefora 10-mg/dL lower levelofApoB-
containing lipoproteins.
The point estimates derived from the individual partici-
pant data and the summary data were then combined across
studies in a fixed-effect inverse variance-weighted meta-
analysis to produce an overall summary point estimate using
apreviously reportedmethod that accounts for correlationbe-
tween variants.19
Effect modification between lowering triglyceride levels
through the LPL pathway and lower LDL-C levels through the
LDL receptor pathwaywas assessedby comparing the associa-
tionsof eachgenetic scorewith the riskofCHDstratifiedby the
other genetic score. The association of combined exposure to
triglyceride-lowering LPL variants and LDL-C–lowering LDLR
variants with the risk of CHDwas evaluated in a 2 × 2 factorial
mendelian randomization analysis.20-23 For both the stratified
and factorial analyses, associations with the risk of CHD were
necessarily restricted to participants with individual data and
associations with changes in triglycerides, LDL-C, and ApoB
werenecessarily restricted toparticipantswith individualdata
for whom 1 ormore lipidmeasurements were available.
Sensitivity Analyses
To compare the potential clinical benefit of pharmacologi-
cally lowering triglyceride and LDL-C levels, the associations
of the LDLR and LPL scores with the risk of CHD per unit dif-
ference inApoBwere comparedwithvariants in thegenes that
encode the targets of current therapies that lower LDL-C
through the LDL receptor pathway; variants in the genes that
encode the targets of potential therapies that lower triglycer-
ides through theLPLpathway; andvariants in theAPOB gene.
To compare the association of triglyceride and LDL-C levels
with the risk of CHDper unit difference inApoBnot related to
theLPLandLDLRgenes, several additionalgenetic scoreswere
constructed using up to 178 genetic variants associated with
either triglycerides, LDL-C, or both at genome-wide signifi-
canceas reportedbytheGlobalLipidsGeneticsConsortium.17,18
To furtherassess the independentassociationsof lower tri-
glycerides, lower LDL-C, and lower ApoB on the risk of CHD,
a multivariable mendelian randomization analysis was per-
formedusing these 178geneticvariants combinedwith theLPL
and LDLR variants. This analysis was performed using meta-
regression analyses in which the dependent variable was the
associated log-odds for the risk of CHD, and the independent
variables were the reported differences in plasma triglycer-
ides, LDL-C, and ApoB for each variant included in the analy-
sis, weighted by the inverse of the squared standard error for
the association of each variant with CHD and forced to pass
through the origin.
All analyses were performed using Stata (version 14.2;
StataCorp), R (version 3.2.2; R Project for Statistical Comput-
ing), or Golden Helix SNP & Variation Suite software (version
8.1.4). A 2-tailed P value less than .05 was considered statis-
tically significant. A detailed description is provided in
eMethods in the Supplement.
Results
Participant Characteristics
A total of 654 783 participants, including 91 129 cases of CHD,
were included in the analysis (mean age, 62.7 years; 51.4%
women). Individualparticipantdatawereavailable for470478
participants including30328casesofCHD(Table 1). Summary-
level datawere available for a further 184 305participants, in-
cluding 60801 cases of CHD.
LPL and LDLRGenetic Scores
A total of 5 independently inherited variantswere included in
the LPL score (eTables 2 and 3 in the Supplement) and 3 inde-
pendently inherited variantswere included in theLDLR score
(eTables 4 and 5 in the Supplement). Each exposure allele in
the LPL score was associated with an inverse variance-
weighted mean of 11.64-mg/dL (95% CI, 10.38-10.90;
P = 8.3 × 10−1365) lowerplasma triglyceride level (to convert to
mmol/L, multiply by 0.0113), 0.11-mg/dL (95% CI, 0.00-0.21;
P = .04)higherplasmaLDL-C level (to convert tommol/L,mul-
tiply by 0.0259, and a 1.72-mg/dL (95% CI, 1.30-2.14;
P = 5.5 × 10−16) lower levelofApoB-containing lipoproteins.By
contrast, each exposure allele in the LDLR score was associ-
ated with an inverse variance-weighted mean of 3.42-mg/dL
(95%CI, 3.27-3.57;P = 2.3 × 10−464) lowerplasmaLDL-C level,
0.48-mg/dL (95%CI, 0.03-0.93;P = .04) lowerplasma triglyc-
eride level, and a 2.40-mg/dL (95% CI, 2.02-2.79;
P = 3.9 × 10−34) lower level of ApoB-containing lipoproteins.
Association of Genetic ScoresWith Lipids
and CHD per Unit Change in ApoB
For each 10-mg/dL lower level of ApoB-containing lipopro-
teins, the LPL scorewas associatedwith 69.9-mg/dL (95%CI,
68.1-71.6;P = 7.1 × 10−1363) lowerplasma triglyceride levels and
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0.7-mg/dL(95%CI,0.03-1.4;P = .04)higherplasmaLDL-C level
(Figure 1). By contrast, for the same 10-mg/dL lower level of
ApoB-containing lipoproteins, the LDLR score was associ-
atedwith 14.2-mg/dL (95%CI, 13.6-14.8;P = 1.4 × 10−465) lower
plasma LDL-C level and 1.9-mg/dL (95% CI, 0.1-3.9; P = .04)
lowerplasma triglyceride level.Despite thesedifferences inas-
sociated lipid levels, the LPL and LDLR scores were associ-
ated with similar lower risk of CHD per 10-mg/dL lower level
of ApoB-containing lipoproteins (odds ratio [OR], 0.771 [95%
CI,0.741-0.802],P = 3.9 × 10−38 for theLPL scoreandOR,0.773
[95%CI, 0.747-0.801],P = 1.1 × 10−46 for theLDLR score). The
associations of the LPL and LDLR scores with the risk of CHD
per unit lowerApoBwas consistent between studies that con-
tributed individual participant data and studies that contrib-
uted summary data (eTable 6 in the Supplement).
In stratifiedanalyses, theassociationsof theLPLandLDLR
scoreswithplasma lipids, lipoproteins, and the riskofCHDap-
peared to be independent of each other (LPL scoreOR for CHD
per 10-mg/dL lower ApoB, 0.771 [95%CI, 0.714-0.832] for par-
ticipants with LDLR scores below themedian and 0.769 [95%
CI,0.709-0.834]forparticipantswithLDLRscoresabovetheme-
dian) (eFigure 4 in the Supplement). In a 2 × 2 factorial men-
delian randomizationanalysis, combinedexposure toboth the
LPL and LDLR genetic scores was associated with linearly ad-
ditive lower levelsof triglyceride (LPL scorealone:−20.1mg/dL
[95%CI,−28.8 to−13.3];LDLR scorealone:−3.8mg/dL [95%CI,
−15.1 to 7.3]; combined exposure to both scores: −24.3 mg/dL
[95% CI, −32.4 to −16.2]), LDL-C levels (LPL score alone:
−0.1mg/dL [95%CI,−0.5 to0.3];LDLR scorealone:−4.8mg/dL
[95% CI, −7.6 to −2.0]; combined exposure to both scores:
−4.9mg/dL [95%CI, −7.7 to −2.1]), and ApoB (LPL score alone:
−3.0mg/dL[95%CI,−4.9to−1.2];LDLRscorealone:−3.4mg/dL
[95% CI, −5.2 to −1.5]; combined exposure to both scores:
−6.4mg/dL [95%CI, −8.5 to −4.4]), aswell as a log-linearly ad-
ditive decreases in the risk of CHD (LPL score alone: OR, 0.924
[95% CI, 0.889-0.960]; LDLR score alone: OR. 0.921 [95% CI:
0.885-0.958]; combined exposure to both scores: OR, 0.842
[95%CI,0.811-0.874]) thatwasproportional to theabsolutedif-
ference inApoBbut not to differences in either triglycerides or
LDL-C (eFigure 5 in the Supplement).
Sensitivity Analyses
In additional analyses, variants in the genes that encode the
targets for several potential therapies that lower triglycerides
through the LPL pathway, and variants in the genes that en-
code the targets of several current therapies that lower LDL-C
through the LDLR pathway, were also associatedwith similar
lower riskofCHDperunitdifference inApoBascomparedwith
theLPL andLDLR scores andas comparedwith anAPOB score
composed of 8 independently inherited variants in theAPOB
gene (Figure 2). Furthermore, the associated lower CHD risk
for each of these variants and genetic scores was log-linearly
proportional to their associated absolute lower level of ApoB-
containing lipoproteins (Figure 3).
Several additional genetic scores consisting of other vari-
ants associated with triglycerides or LDL-C at genome-wide
level of significance (excluding variants in the LPL and LDLR
genes)—including scores consistingofvariants associatedwith
either triglyceridesorLDL-C; triglyceridesbutnotLDL-C;LDL-C
but not triglycerides; both triglycerides and LDL-C with the
samedirectionofeffect; andboth triglyceridesandLDL-Cwith
opposite directions of effect—were also associated with simi-
lar lower risk of CHD per 10-mg/dL lower level of ApoB-
containing lipoproteins (Table 2). Inmultivariablemendelian
randomization analyses that included both triglycerides and
LDL-C in the samemodel, theassociationsbetweenplasma tri-
glycerides and LDL-Cwith the risk of CHDwere independent
andgenome-widesignificant.However,whenchanges inApoB
were included in theseanalyses, theassociationsbetweenboth
plasma triglycerides and LDL-C with the risk of CHD became
null (triglycerides: OR, 1.014 [95% CI, 0.965-1.065], P = .19;
Table 1. Baseline Characteristics of Study Participantsa
Characteristic
Participant
Baseline
Characteristics
No. of
Participants With
Available Data
for Each Baseline
Characteristic
Sample size, No. 654 783 654 783
CHD cases, No. 91 129 654 783
Age, mean (SD), y 62.7 (8.1) 654 783
Sex
Women, No. (%) 336 462 (51.4) 654 783
Men, No. (%) 318 321 (48.6) 654 783
Blood pressure,
mean (SD), mm Hg
Systolic 132.1 (18.2) 470 478
Diastolic 80.9 (9.3) 470 478
Body mass index,
mean (SD)b
27.5 (4.9) 470 478
Prevalent diabetes, No. (%) 21 642 (4.6) 470 478
Current smoker, No. (%) 43 284 (9.2) 470 478
Cholesterol,
mean (SD), mg/dL
Total 206.6 (39.4) 31 221
Low-density lipoprotein 129.7 (32.1) 31 221
High-density lipoprotein 52.0 (15.4) 31 221
Triglycerides,
median (IQR), mg/dL
117.6 (84.1-163.3) 31 221
Apolipoprotein B,
mean (SD), mg/dL
101.4 (27.3) 31 221
Non–high-density
lipoprotein cholesterol
(total cholesterol−HDL-C),
mean (SD), mg/dL
154.9 (38.3) 31 221
Remnant cholesterol
(total cholesterol−HDL-C−LDL-C),
median (IQR), mg/dL
23.9 (15.9-32.8) 31 221
Abbreviations: CHD, coronary heart disease; IQR, interquartile range.
SI conversion factors: To convert cholesterol to mmol/L, multiply by 0.0259;
triglycerides to mmol/L, multiply by 0.0113.
a Data for age and sex were available for all 654 783 participants included in the
primary analysis. Data for other nonlipid baseline characteristics were
available for 470478 participants with individual-level data enrolled in the UK
Biobank or 1 of the 14 case-control or cohort studies that reported
cardiovascular outcomes in the database of genotypes and phenotypes
program (dbGAP). Data for baseline lipid measurements were available for
31 221 participants with individual data enrolled in 1 of the dbGAP studies and
for whom lipid measurements were available (the UK Biobank has not yet
released lipid measurements of enrolled participants). Non–high-density
lipoprotein cholesterol and remnant cholesterol levels are calculated values.
b Calculated as weight in kilograms divided by height in meters squared.
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LDL-C:OR, 1.010 [95%CI,0.967-1.055],P = .19; andApoB:OR,
0.761 [95%CI,0.723-0.798],P = 7.51 × 10−20) (Table3; eTable8
in the Supplement).
Discussion
In this study, triglyceride-lowering LPL variants and LDL-C–
loweringLDLRvariantswereassociatedwithsimilar lowerCHD
risk per unit lower level of ApoB-containing lipoproteins. The
associationsbetween lower triglyceride level and lowerLDL-C
levelwith risk of CHDdue to these variants appeared to be in-
dependent, additive, andproportional to the absolute change
in ApoB. In addition, numerous variants in the genes that en-
code the targets of potential therapies that lower triglyceride
levels through the LPL pathway and current therapies that
lower LDL-C levels through the LDLR pathway were also as-
sociated with similar lower CHD risk per unit lower plasma
ApoB levels. Furthermore,multiple genetic scores composed
of other variants associated with either triglycerides, LDL-C,
or bothwere also associatedwith similar lower riskofCHDper
unit lower level of ApoB-containing particles, even when the
associatedchanges in triglycerideandLDL-C levelswere inop-
posite directions. In multivariable mendelian randomization
analyses, the independent and genome-wide significant as-
sociationsbetweentriglyceridesandLDL-CwiththeriskofCHD
became null after adjusting for changes in ApoB.
The results of this study suggest that the clinical benefit of
lowering triglyceride levels is similar to the clinical benefit
of loweringLDL-C levelsperunit change inApoBand ispropor-
tional to thenetabsolute reduction inApoB-containing lipopro-
teins. The results of this study therefore suggest that all ApoB-
containing lipoprotein particles, including triglyceride-rich
very-low-density lipoprotein (VLDL) particles and their meta-
bolic remnantsaswell asLDLparticles,haveapproximately the
sameeffecton the riskof cardiovasculardiseaseperparticle.As
a result, the clinical benefit of lowering triglyceride levels, low-
eringLDL-C levels, or loweringbothmaybeproportional to the
absolute change inApoB-containing lipoproteins, regardless of
the observed changes in plasma triglycerides or LDL-C.
The resultsof this studyareconsistentwith thecurrentun-
derstanding of the biology of lipids and atherosclerosis. Both
triglycerides and cholesterol are carried in plasma by ApoB-
containing lipoproteinparticles.Theseparticlesare secretedby
the liver asVLDLparticles,whichprincipally contain triglycer-
ides, somecholesterol, and 1molecule ofApoB. Lipoprotein li-
pase removes most of the triglycerides from these particles to
convert the triglyceride-rich VLDL particles into triglyceride-
depletedcholesterol-carryingLDLparticles,whichare then re-
moved from plasma by hepatic LDL receptors. All ApoB-
containing lipoproteins less than 70nm indiameter, including
triglyceride-rich VLDL remnants and LDL particles, freely flux
across the endothelial barrierwhere they canbecome retained
in the artery wall.24 The cholesterol, and perhaps triglyceride,
content of the ApoB particles retained in the artery wall pro-
vokesan inflammatory response that leads to the initiationand
progressionofatheroscleroticplaque.25Theresultsof thisstudy
suggest that the effect of ApoB-containingparticles on the risk
of atherosclerotic cardiovascular disease appears to be deter-
mined largely by the concentration of circulating ApoB par-
ticles,which in turndetermines thenumberofparticles thatbe-
come retained in the artery wall, regardless of whether those
particlesprincipallycontaincholesterolor triglycerides.Thepre-
sent findingsand interpretationsbasedonmendelian random-
ization confirm and extend the initial findings and interpreta-
tions in 1980ofSnidermanandcolleagues,26whichwerebased
on cross-sectional coronary angiographic studies.
The resultsof this studyarealsoconsistentwithpriormen-
delian randomization studiesdemonstrating that triglyceride-
richApoB-containing remnant particles appear to be causally
Figure 1. Associations Between the Lipoprotein Lipase (LPL) and LDL Receptor Gene (LDLR) Genetic ScoresWith Triglycerides,
Low-Density Lipoprotein Cholesterol (LDL-C), and Risk of Coronary Heart Disease (CHD) per 10-mg/dL Lower Concentration
of Apolipoprotein B (ApoB)–Containing Lipoproteins
P Value
Genetic
Score
Δ Low-Density
Lipoprotein
Cholesterol (95% CI)
Odds Ratio for
Coronary Heart
Disease (95% CI)
7.1 × 10–1363LPL 0.7 (0.0 to 1.4) 0.771 (0.741 to 0.802)
.04
P Value
.04
1.4 × 10–465
P Value
3.9 × 10–38
1.1 × 10–46LDLR –14.2 (–14.8 to –13.6)
Δ Triglycerides
(95% CI)
–69.9 (–71.6 to –68.3)
–1.9 (–3.9 to –0.1) 0.773 (0.747 to 0.801)
1 20.5
Odds Ratio for CHD per 10-mg/dL Lower
Plasma ApoB Concentration (95% CI)
Triglycerides are carried in plasma by ApoB-containing triglyceride-rich
lipoproteinswhile cholesterol is carried predominantly by ApoB-containing
low-density lipoproteins. Changes in plasma triglycerides and LDL-C
concentration are thusmarkers of the corresponding changes in the
concentration of the ApoB-containing lipoproteins that transport these lipids.
Variants in the LPL gene that increase LPL activity are associatedwith lower
triglycerides and a corresponding lower ApoB concentration, while variants in the
LDLR gene that increase activity of the LDL receptor are associatedwith lower
LDL-C and a corresponding lower ApoB. The figure shows that for each 10-mg/dL
lower plasma ApoB concentration associatedwith variants in the LPL score, there
is a corresponding 69.9-mg/dL lower triglyceride level, no change in LDL-C,
and a lower risk of CHD (odds ratio, 0.771 [95%CI, 0.741-0.802]). By contrast,
for the same 10-mg/dL lower plasma ApoB concentration associatedwith variants
in the LDLR score, there is a corresponding 14.1-mg/dL lower LDL-C level, no
change in triglycerides, and a similar lower risk of CHD (odds ratio, 0.773 [95%CI,
0.747-0.801]). Therefore, despite being associatedwith changes in different
lipids, the LPL and LDLR scoreswere associatedwith similar lower risk of CHD for
the same lower plasma ApoB concentration. The data presented are for the
associations of the LPL and LDLR genetic scoreswith risk of CHDper 10-mg/dL
decrease in ApoB-containing lipoproteins in all 654 783 participants included in
the study. The associations of either scorewith changes in triglycerides and LDL-C
per 10-mg/dL lower level of ApoB-containing lipoproteins are fromup to 305699
participants enrolled in the Global Lipid Genetics Consortium. Boxes represent
effect size estimates and lines represent 95%CIs.
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associatedwith the risk of cardiovascular disease.27,28 The re-
sults of the current study extend those findings by suggest-
ing that triglyceride-rich remnant particles have approxi-
mately the same effect on the risk of cardiovascular disease
asLDLparticles.Furthermore, the resultsof this studyare con-
sistentwitha recentmendelian randomizationstudythatdem-
onstrated that the causal effect of LDL particles on the risk of
cardiovascular disease appears to be determined by the con-
centration of circulating LDL particles as measured by ApoB
rather than by the mass of cholesterol carried by those par-
ticles asmeasuredbyLDL-C.23The results of the current study
confirmandextendthose findingsbysuggesting that thecausal
effect of all ApoB-containing lipoprotein particles on the risk
of cardiovascular disease appears to bedeterminedby the cir-
culating concentration of those particles rather than by the
mass of cholesterol or triglyceride that they carry.
The resultsof this studymayalsohelp toexplainwhyprior
randomized trials evaluating fibrates, which lower plasma tri-
glyceride levelsat leastpartially throughtheLPLpathway,have
failedtoconsistentlydemonstrate that loweringtriglyceride lev-
els reduces the risk of cardiovascular events.29-33 The concen-
trationof triglyceride-rich lipoproteins canbe estimatedbydi-
viding plasma triglyceride concentration by 5 (on the mg/dL
scale).Therefore, if allApoB-containingparticleshaveapproxi-
mately the same atherogenic effect as suggested by this study,
then to reduce the risk of cardiovascular events by 20%as can
beachievedby loweringLDL-C levelsby40mg/dL,3,4 triglycer-
ide levels must be reduced by 5-fold this quantity, or approxi-
mately200mg/dL,toachievethesamecorrespondingreduction
inApoB-containing lipoproteins.However, themeanreduction
inplasmatriglycerideconcentration inthefibrate trialswasonly
20mg/dLto50mg/dL,afractionofwhatwouldbeneededtosig-
nificantlyreducetheriskofmajorvasculareventswithinashort-
term trial. Therefore, the results of the fibrate trials appear to
be explained by the modest reductions in triglyceride level
and therefore the modest corresponding reductions in ApoB-
containing lipoproteins observed in these studies. Future ran-
domized trials evaluating novel therapies that lower plasma
triglyceride levels shouldbedesignedbasedonthenetabsolute
reductions inApoB-containinglipoproteinsthatcanbeachieved
withthosetherapies,ratherthanonthecorrespondingtherapeu-
tic changes in triglycerides or LDL-C, particularly for therapies
thatalterplasmaconcentrationsofbothtriglyceridesandLDL-C
either in the same or competing directions.
Limitations
This study has several limitations. First, this study compared
triglyceride- and LDL-C–lowering genetic variants not lipid-
lowering therapies.Second,geneticvariants reflect theeffectof
lifelongchanges inApoB-containing lipoproteinson the riskof
cardiovascular disease, which appear to be cumulative over
time.5,34Asa result, the lower riskassociatedwith lower triglyc-
erides,LDL-C,andApoBreportedinthisstudyismuchlargerthan
whathavebeenreportedfor lipid-loweringtherapies inrandom-
izedtrials.However,havingfirstestablishedthat theassociation
between lifetimeexposure to lower triglycerides andLDL-Con
theriskofcardiovasculardisease isapproximately thesameper
unit lower levelofApoB-containingparticles, it is reasonable to
Figure 3. Log-Linear Association Between Absolute Differences in Apolipoprotein B (ApoB) and Lower Risk of Coronary Heart Disease (CHD)
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The associations of each genetic variant with ApoB concentration is plotted
against its unadjusted association with CHD, expressed as a proportional lower
risk (calculated as [1−ORCHD]×100). Variants in the genes that encode the
targets of therapies that lower triglycerides through the LPL pathway are
marked with blue labels, and variants in the genes that encode the targets of
therapies that lower LDL-C through upregulation of the LDL receptor are
marked by red labels. Circles represent the associated absolute change in ApoB
and corresponding proportional lower risk of CHD for each variant.
The horizontal lines through each circle represents ±1 standard errors
for the associated absolute change in ApoB for each variant; and the vertical
line through each circle represents ±1 standard errors for the associated
proportional lower risk of CHD. Associations with CHDweremeasured in all
654 783 participants included in the study; associations with ApoBwere
measured in a meta-analysis of 14 studies including up to 84 324 participants.
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Table 3. MultivariableMendelian Randomization Analysis of the Association Between Plasma Triglycerides, LDL-C, and ApoBWith the Risk of CHDa
Analysis Variables
Odds Ratio for CHD
(95% CI) P Value
Association of 10-mg/dL lower ApoB with risk of CHD ApoB 0.770 (0.760-0.781) 1.42E-170
Association of 10-mg/dL lower LDL-C with risk of CHD LDL-C 0.846 (0.833-0.858) 8.16E-77
Association of 50-mg/dL lower triglycerides with risk of CHD Triglycerides 0.815 (0.785-0.846) 1.37E-18
Association of 10-mg/dL lower LDL-C and 50-mg/dL lower
triglycerides with risk of CHD included in same model
LDL-C 0.862 (0.849-0.875) 6.92E-65
Triglycerides 0.876 (0.850-0.902) 1.36E-14
Association of 10-mg/dL lower LDL-C, 50-mg/dL lower
triglycerides, and 10-mg/dL lower ApoB with risk of CHD
included in same model
ApoB 0.761 (0.723-0.798) 7.51E-20
LDL-C 1.010 (0.967-1.055) .19
Triglycerides 1.014 (0.965-1.065) .19
Abbreviations: ApoB, apolipoprotein B; CHD, coronary heart disease;
LDL-C, low-density lipoprotein cholesterol.
a Data presented are derived from amultivariable meta-regression analysis of
186 genetic variants, including the 5 variants included in the LPL score, 3
variants included in the LDLR score, and 178 variants associated with either
triglycerides, LDL-C, or both at genome-wide significance as reported by the
Global Lipids Genetics Consortium. Effect sizes for the associated risk of CHD
are reported per 10-mg/dL lower ApoB concentration, per 10-mg/dL lower
LDL-C level, or per 50-mg/dL lower triglyceride level (because dividing
triglyceride concentration by 5 estimates the cholesterol content carried by
triglyceride-rich ApoB-containing lipoproteins as estimated by the Friedewald
formula). In these analyses, the dependent variable was the effect estimate for
risk of CHD in all 654 783 participants included in the study for each variant
and the independent variables were the effect estimates for the associated
changes in plasma triglycerides, LDL-C, and ApoB, measured in up to 305699
participants in Global Lipids Genetics Consortium for each variant. The analysis
was weighted by the inverse squared standard error of the associated risk of
CHD for each variant and forced to pass through the origin. For example, in
multivariable mendelian randomization analyses involving these 186 genetic
variants, both triglycerides (odds ratio [OR], 0.876 per 50-mg/dL lower
triglycerides) and LDL-C (OR, 0.862 per 10-mg/dL lower LDL-C) were
independently associated with a lower risk of CHD at genome-wide level of
significance. By contrast, when ApoBwas included in themultivariable
mendelian randomization analyses, the associations with CHD for both
triglycerides (OR, 1.014 per 50-mg/dL lower triglycerides) and LDL-C
(OR, 1.010 per 10-mg/dL lower LDL-C) became null, but the association per
10-mg/dL lower ApoB remained unchanged (OR, 0.761 per 10-mg/dL lower
ApoB). The unadjusted associations with triglycerides, LDL-C, ApoB, and CHD
for each variant included in the analysis are provided in eTable 7 in the
Supplement. Additional multivariable meta-regression analyses for various
combinations of these variants is provided in eTable 8 in the Supplement.
Table 2. Association of Additional Genetic ScoresWith Triglycerides, LDL-C, and Risk of CHD per 10-mg/dL Lower Concentration
of ApoB-Containing Lipoproteinsa
Composition of Genetic Score Δ Triglycerides (95% CI) Δ LDL-C (95% CI)
Odds Ratio for CHD (95% CI)
per 10-mg/dL Lower ApoB
51 Variants associated with triglycerides at P < 5.0×10−8,
but not LDL-C (P > .001)
−43.1 (−44.5 to −41.7) −2.1 (−2.6 to −1.6) 0.762 (0.724 to 0.803)
59 Variants associated with LDL-C at P < 5.0×10−8,
but not triglycerides (P > .001)
−2.1 (−3.0 to −1.1) −15.5 (−15.8 to −15.1) 0.774 (0.748 to 0.800)
168 Variants associated with either triglycerides or LDL-C
at P < 5.0×10−8
−21.6 (−22.1 to −21.1) −11.8 (−12.0 to −11.6) 0.770 (0.757 to 0.783)
91 Variants associated with triglycerides at P < 5.0×10−8 −35.3 (−35.9 to −34.6) −9.3 (−9.6 to −9.1) 0.776 (0.758 to 0.795)
100 Variants associated with LDL-C at P < 5.0×10−8 −17.5 (−18.0 to −17.0) −13.5 (−13.7 to −13.3) 0.776 (0.762 to 0.791)
23 Variants associated with both triglycerides and LDL-C,
both at P < 5.0×10−8, in same direction of effect
−32.3 (−33.0 to −31.5) −12.0 (−12.3 to −11.7) 0.793 (0.771 to 0.815)
10 Variants associated with both triglycerides and LDL-C,
both at P < 5.0×10−8, with opposite directions of effect
17.2 (16.0 to 18.4) −22.5 (−23.0 to −22.1) 0.798 (0.767 to 0.830)
9 Variants associated with both triglycerides and LDL-C,
both at P < 5.0×10−8, with opposite directions of effect
(excluding APOE variant rs7412)
26.0 (23.7 to 28.3) −20.3 (−21.2 to −19.4) 0.770 (0.711 to 0.833)
Abbreviations: ApoB, apolipoprotein B; CHD, coronary heart disease;
LDL-C, low-density lipoprotein cholesterol; OR, odds ratio.
a To compare the association of triglycerides and LDL-C with the risk of CHD
for the same lower concentration of ApoB-containing lipoproteins not related
to the LPL and LDLR genes, several additional genetic scores were constructed
using up to 178 genetic variants associated with either triglycerides, LDL-C,
or both at genome-wide significance as reported by the Global Lipids Genetics
Consortium (GLGC). The data presented are for the associations of each
genetic score with changes in triglycerides and LDL-C per 10-mg/dL lower
ApoB in up to 305699 participants in the GLGC and with the risk of CHD per
10-mg/dL lower ApoB in all 654 783 participants included in this study.
For example, for each 10-mg/dL lower plasma ApoB concentration associated
with a genetic score consisting of 51 variants associated with triglycerides but
not LDL-C at genome-wide level of significance, there was a corresponding
41.3-mg/dL lower triglyceride level, 2.1-mg/dL lower LDL-C level, and a lower
risk of CHD (odds ratio [OR], 0.762 [95% CI, 0.724-0.803]). By contrast,
for the same 10-mg/dL lower plasma ApoB concentration associated with
a genetic score consisting of 59 variants associated with LDL-C but not
triglycerides at genome-wide level of significance, there was a corresponding
15.5-mg/dL lower LDL-C level, 2.1-mg/dL lower triglyceride level, and a similar
lower risk of CHD (OR, 0.774 [95% CI, 0.748-0.800]). Furthermore,
for the same 10-mg/dL lower plasma ApoB concentration associated with
a genetic score consisting of 168 variants associated with either triglycerides
or LDL-C at genome-wide level of significance, there was a corresponding
21.6-mg/dL lower triglyceride level, an 11.8-mg/dL lower LDL-C level, and
a similar lower risk of CHD (OR, 0.770 [95% CI, 0.757-0.783]). Despite being
associated with different changes in lipids, all genetic scores were associated
with similar lower risk of CHD for the same 10-mg/dL lower plasma ApoB
concentration. The unadjusted associations with triglycerides, LDL-C, ApoB,
and CHD for each variant included in the genetic scores are provided in
eTable 7 in the Supplement.
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then anticipate that short-term pharmacologic reductions in
plasmatriglycerideandLDL-C levelswill beassociatedwith the
same lower risk of cardiovascular events per unit change in
ApoB.21Third, this studyspecificallyestimates theclinicalben-
efit of the lipid-lowering effect of therapies that reduceplasma
triglycerides, LDL-C, or both, but not the other potential pleio-
tropic effects that a therapymay have on the risk of cardiovas-
cular disease. Indeed, the reported reductions in cardiovascu-
larevents intheJELISandREDUCE-ITtrialswerefargreaterthan
what would have been expected from the modest observed
changes inplasmalipid levels, thussuggestingthat theobserved
clinical benefit of theomega-3 fatty acideicosapentaenoic acid
may be largely due to its non–lipid-related effects.35,36
Conclusions
Triglyceride-loweringLPLvariants andLDL-C–loweringLDLR
variantswereassociatedwithsimilar lower riskofCHDperunit
difference inApoB. Therefore, the clinical benefit of lowering
triglyceride and LDL-C levels may be proportional to the ab-
solute change in ApoB.
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